Louisiana woman developed retinal damage after using Elmiron

Event News

Picture of Researcher: Ariana Arce​

Researcher: Ariana Arce​


Picture of Journalist: Aaron Vivanco

Journalist: Aaron Vivanco


Picture of Editor: Daniela Polo

Editor: Daniela Polo


Contact Us

We will review your case so that we can help you become a part of the lawsuit to hold the company accountable.

Louisiana woman developed retinal damage after using Elmiron

Lawsuit update

At the end of October 2022, the Court issued an order stating that the bellwether trial scheduled for January 2023 will be adjourned until March 27, 20231. This trial is in regard to Maria Windham’s case vs. Janssen Pharmaceuticals, Inc. Maria, a woman from Louisiana, used Elmiron and subsequently developed pigmentary changes and retinal damage2.

As of October 12, 1,926 cases alleging product liability claims against Elmiron have been filed and served (1,680 federal and 169 state cases)3.

Elmiron eye damage symptoms

Signs of Elmiron eye damage include pigmentary maculopathy, retinal maculopathy, and macular degeneration. Among the symptoms of Elmiron damage are blurred vision, eye pain, increased sensitivity to light, and dark spots in the field of vision4.

Exposure to pentosan polysulfate sodium, the active substance in Elmiron, has been identified as an important, if not the most important factor in the development of pigmentary maculopathy5.

As of June 8, 2022, attorneys have filed and served 1,041 product liability claims relating to the use of Elmiron (915 federal and 126 in state courts). The total number of cases pending as of September 2022 in the Elmiron MDL was 1,774, and the first bellwether test trial is set to go forward in January. This will be followed by a second trial in March and a third test trial in May.6


1. https://www.njd.uscourts.gov/sites/njd/files/MDL2973_OrderAdjTrialDate.pdf 



4.https://www.forbes.com/advisor/legal/product-liability/elmiron-lawsuit-update/ 5.https://pubmed.ncbi.nlm.nih.gov/34792558/